Visual Loss without Headache in Children with Pseudotumor Cerebri and Growth Hormone Treatment

Abstract

We report on two prepubescent girls with visual loss due to idiopathic intracranial hypertension (IIH), or pseudotumor cerebri, both treated with recombinant human growth hormone for growth failure. The interval from starting hormone therapy to diagnosis of IIH was 3 and 18 months, respectively. Both girls did not complain of headache and nausea. They were neither obese nor did they suffer from renal insufficiency. In both patients, we observed bilateral optic disc edema with visual loss and elevated cerebrospinal fluid (CSF) pressures. Other causes of IIH were excluded with neuroimaging and CSF examination. Cessation of drug administration is often sufficient for symptom resolution in cases of hormone therapy–associated IIH. However, visual field defects in one girl remained unchanged during follow-up of 8 months. In children with IIH, the spectrum of neurologic and visual manifestations might be variable and unspecific. Diagnosis and management of IIH can be difficult in the absence of headache. Blurred or double vision due to cranial nerve palsy might be the only symptom rather than complaints about reduced visual acuity. Therefore, regular clinical monitoring of visual function and fundus appearance is essential for early diagnosis, efficient management, and improvement of visual outcome in children receiving recombinant human growth hormone.

Keywords

pediatric pseudotumor cerebri - pediatric idiopathic intracranial hypertension - growth hormone - papilledema - visual loss

• References

• 1 Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 2010; 74 (6) 381-389
• 2 Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship?. J Pediatr Endocrinol Metab 2002; 15 (Suppl. 02) 723-730
• 3 Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83 (5) 488-494 Review
• 4 Lim M, Kurian M, Penn A, Calver D, Lin J-P. Visual failure without headache in idiopathic intracranial hypertension. Arch Dis Child 2005; 90 (2) 206-210
• 5 Avery RA, Licht DJ, Shah SS , et al. CSF opening pressure in children with optic nerve head edema. Neurology 2011; 76 (19) 1658-1661
• 6 Rogers AH, Rogers GL, Bremer DL, McGregor ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 1999; 106 (6) 1186-1189 , discussion 1189–1190
• 7 Koller EA, Stadel BV, Malozowski SN. Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997; 11 (4) 451-454
• 8 Maralani PJ, Hassanlou M, Torres C , et al. Accuracy of brain imaging in the diagnosis of idiopathic intracranial hypertension. Clin Radiol 2012; 67 (7) 656-663
• 9 Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007; 52 (6) 597-617
• 10 Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995; 126 (6) 996-999